Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 201–300 of 1,000
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“However, in pathological conditions glutamate can act as a neuronal excitotoxin, leading to rapid or delayed neurotoxicity [34].”
BackgroundJiménez-Sánchez, L., Castañé, A., Pérez-Caballero, L., Grifoll, M., López-Gil, X., Campa, L., Galofré, M., Berrocoso, E., & Adell, A. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhv133 · Cited by 83
Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82
Local Thyroid Hormone Action in Brain Development
Alcaide, M. A., & Mayerl, S. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512352 · Cited by 82
The Roles of Neurotrophic Factor and Wnt Signaling in Depression
Voleti, B., & Duman, R. S. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.296 · Cited by 77
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Yoon, S. J., Lyoo, I. K., Haws, C. A., Kim, T. S., Cohen, B. M., & Renshaw, P. F. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.2 · Cited by 81
Prisciandaro, J. J., Tolliver, B. K., Prescot, A. P., Brenner, H. M., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.141 · Cited by 80
Onaolapo, A. Y., & Onaolapo, O. J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.297 · Cited by 80
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
“LY392098, cyclothiazide, CX-516) to treat depression (Alt et al. 2005; Sanacora et al. 2008).”
Kiemes, A., Davies, C., Kempton, M. J., Lukow, P. B., Bennallick, C., Stone, J. M., & Modinos, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.644315 · Cited by 79
Lin, T., Lü, C.-W., Wang, C., Wang, Y., & Wang, S. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.012 · Cited by 79
Vitamin D 3 Supplemental Treatment for Mania in Youth with Bipolar Spectrum Disorders
Şıkoğlu, E. M., Navarro, A. A. L., Starr, D., Dvir, Y., Nwosu, B. U., Czerniak, S., Rogan, R. C., Castro, M. C., Edden, R. A. E., Frazier, J. A., et al. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0110 · Cited by 77
Pozzi, L., Dorocic, I. P., Wang, X., Carlén, M., & Meletis, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083879 · Cited by 74
“Recent insights relevant for the development of faster acting antidepressants have come from the discovery that compounds targeting the glutamatergic system have acute antidepressant effects [2].”
BackgroundLv, Q., Yang, L., Li, G., Wang, Z., Shen, Z., Yu, W., Jiang, Q., Hou, B., Pu, J., Hu, H., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.028 · Cited by 74
Réus, G. Z., Abelaira, H. M., dos Santos, M. A. B., Carlessi, A. S., Tomaz, D. B., Neotti, M. V., Liranço, J. L. G., Gubert, C., Barth, M., Kapczinski, F. P., et al. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.041 · Cited by 74
Barbon, A., Caracciolo, L., Orlandi, C., Musazzi, L., Mallei, A., Via, L. L., Bonini, D., Mora, C., Tardito, D., Gennarelli, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.013 · Cited by 74
Janssen, D., & Kozicz, T. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00028 · Cited by 74
Abdallah, C. G., Coplan, J. D., Jackowski, A., Sato, J. R., Mao, X., Shungu, D. C., & Mathew, S. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.009 · Cited by 66
mGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73
Glutathione is a physiologic reservoir of neuronal glutamate
Koga, M., Serritella, A. V., Messmer, M. M., Hayashi-Takagi, A., Hester, L. D., Snyder, S. H., Sawa, A., & Sedlak, T. W. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.087 · Cited by 73
“Substantial proportions of glutamate neurotransmitter pools (50-60%) have long thought to be derived from the glutamine-glutamate shuttle [16,17], with much smaller amounts arising from glycolysis [18-20].”
BackgroundEriksson, T. M., Delagrange, P., Spedding, M., Popoli, M., Mathé, A. A., Ögren, S. O., & Svenningsson, P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.131 · Cited by 73
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 69
Laugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.008 · Cited by 72
Moretti, M., Freitas, A. E., Budni, J., Fernandes, S. C. P., Balen, G. O., & Rodrigues, A. L. S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.024 · Cited by 72
Li, M., Demenescu, L. R., Čolić, L., Metzger, C. D., Heinze, H., Steiner, J., Speck, O., Fejtová, A., Salvadore, G., & Walter, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.184 · Cited by 72
Monn, J. A., Prieto, L., Taboada, L., Pedregal, C., Hao, J., Reinhard, M. R., Henry, S. S., Goldsmith, P. J., Beadle, C. D., Walton, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501612y · Cited by 71
Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling
Neis, V. B., Moretti, M., Bettio, L. E. B., Ribeiro, C. M., da Rosa, P. B., Gonçalves, F. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.009 · Cited by 71
Terbeck, S., Akkus, F., Chesterman, L. P., & Hasler, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00086 · Cited by 70
Molecular mechanisms of psychiatric diseases
Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 69
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Tsai, S., Hsu, P., Chen, Y., Hossain, M. S., Chen, P., Tzeng, S., Chen, P. S., & Kuo, Y. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01787-1 · Cited by 69
Cognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
“…evidence suggests that depression is also associated with alterations in other neurotransmitter systems (such as glutamatergic transmission), as well as to a loss of synaptic plasticity in circuits involved in regulating mood and emotions (Sanacora et al., 2008; Kavalali and Monteggia, 2012).”
BackgroundSoumier, A., Carter, R. M., Schoenfeld, T. J., & Cameron, H. A. (2016) · eneuro · doi:10.1523/eneuro.0116-15.2016 · Cited by 67
Elevated peripheral blood glutamate levels in major depressive disorder
Inoshita, M., Umehara, H., Watanabe, S.-Y., Nakataki, M., Kinoshita, M., Tomioka, Y., Tajima, A., Numata, S., & Ohmori, T. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s159855 · Cited by 67
Gruenbaum, B. F., Zlotnik, A. A., Fleidervish, I. A., Frenkel, A., & Boyko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179628 · Cited by 67
Dynamics of glutamatergic signaling in the mushroom body of young adult Drosophila
Sinakevitch, I. G., Grau, Y., Strausfeld, N. J., & Birman, S. (2010) · Neural Development · doi:10.1186/1749-8104-5-10 · Cited by 67
Salimando, G. J., Hyun, M., Boyt, K. M., & Winder, D. G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0270-20.2020 · Cited by 67
Han, W., Du, P., Fu, S.-Y., Wang, F., Song, M., Wu, C., & Yang, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.014 · Cited by 66
Wilson, M. A., Grillo, C. A., Fadel, J. R., & Reagan, L. P. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.06.001 · Cited by 66
Croarkin, P. E., Nakonezny, P. A., Husain, M. M., Melton, T., Buyukdura, J. S., Kennard, B. D., Emslie, G. J., Kozel, F. A., & Daskalakis, Z. J. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.24 · Cited by 65
“Prior animal research suggests that stress and glucocorticoids may collectively upregulate glutamate neurotransmission through increased presynaptic release and reduced clearance.(16) Our findings suggest that children and adolescents with MDD have excessive cortical excitability mediated by NMDA receptors.”
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nurnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 65
Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder
Ehrlich, A., Schubert, F., Pehrs, C., & Gallinat, J. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.05.010 · Cited by 65
Molteni, R., Chourbaji, S., Brandwein, C., Racagni, G., Gass, P., & Riva, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099815 · Cited by 57
The role of purinergic signaling in depressive disorders.
Sperlágh, B., Csölle, C., Andó, R. D., Gölöncsér, F., Kittel, Á., & Baranyi, M. (2012) · PubMed · Cited by 64
New Therapeutic Targets for Mood Disorders
Machado-Vieira, R., Salvadore, G., DiazGranados, N., Ibrahim, L., Latov, D., Wheeler-Castillo, C., Baumann, J., Henter, I. D., & Zarate, C. A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.65 · Cited by 63
Self-citationEvidence for Impaired Neocortical Synaptic Plasticity in Bipolar II Disorder
Elvsåshagen, T., Moberget, T., Bøen, E., Boye, B., Englin, N. O. A., Pedersen, P. Ø., Andreassen, O. A., Dietrichs, E., Malt, U. F., & Andersson, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.026 · Cited by 63
Masrour, F. F., Peeri, M., Azarbayjani, M. A., & Hosseini, M. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2519-6 · Cited by 63
Millard, S. J., Weston-Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109908 · Cited by 62
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Monn, J. A., Prieto, L., Taboada, L., Hao, J., Reinhard, M. R., Henry, S. S., Beadle, C. D., Walton, L., Man, T., Rudyk, H., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01124 · Cited by 62
Short‐ and long‐term antidepressant effects of ketamine in a rat chronic unpredictable stress model
Jiang, Y., Wang, Y., Sun, X., Lian, B., Sun, H., Wang, G., Du, Z., Li, Q., & Sun, L. (2017) · Brain and Behavior · doi:10.1002/brb3.749 · Cited by 62
Integrin adhesion in brain assembly: From molecular structure to neuropsychiatric disorders
Jaudon, F., Thalhammer, A., & Cingolani, L. A. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14859 · Cited by 62
Zeni, A. L. B., Zomkowski, A. D. E., Dal-Cim, T. A., Maraschin, M., Rodrigues, A. L. S., & Tasca, C. I. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.07.009 · Cited by 61
Fuchs, A., Boesiger, P., Schulte, R. F., & Henning, A. (2013) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24703 · Cited by 60
Pålsson, E., Jakobsson, J., Södersten, K., Fujita, Y., Sellgren, C. M., Ekman, C. J., Ågren, H., Hashimoto, K., & Landén, M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.001 · Cited by 60
Triple Reuptake Inhibitors as Potential Next-Generation Antidepressants: A New Hope?
Sharma, H., Santra, S., & Dutta, A. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.134 · Cited by 60
Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration
Neis, V. B., Manosso, L. M., Moretti, M., Freitas, A. E., Daufenbach, J., & Rodrigues, A. L. S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.12.038 · Cited by 59
New Frontiers in Animal Research of Psychiatric Illness
Kaffman, A., & Krystal, J. J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-458-2_1 · Cited by 59
Self-citationStructural connectivity and response to ketamine therapy in major depression: A preliminary study
Vasavada, M. M., Leaver, A. M., Espinoza, R. T., Joshi, S. H., Njau, S. N., Woods, R. P., & Narr, K. L. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.018 · Cited by 59
Kiselycznyk, C., Jury, N. J., Halladay, L. R., Nakazawa, K., Mishina, M., Sprengel, R., Grant, S. G. N., Svenningsson, P., & Holmes, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.023 · Cited by 56
Agmatine, a potential novel therapeutic strategy for depression
Freitas, A. E., Neis, V. B., & Rodrigues, A. L. S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.013 · Cited by 59
Bradley, S. R., Uslaner, J. M., Flick, R., Lee, A., Groover, K. M., & Hutson, P. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.11.006 · Cited by 58
Increased serum levels of serine enantiomers in patients with depression
Hashimoto, K., Yoshida, T., Ishikawa, M., Fujita, Y., Niitsu, T., Nakazato, M., Watanabe, H., Sasaki, T. G., Shiina, A., Hashimoto, T., et al. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.59 · Cited by 58
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 58
Zhu, X., Nedelcovych, M. T., Thomas, A. G., Hasegawa, Y., Moreno-Megui, A., Coomer, W., Vohra, V., Saito, A., Perez, G., Wu, Y., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0177-7 · Cited by 57
Farley, S., Dumas, S., Mestikawy, S. E., & Giros, B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.09.010 · Cited by 56
Clinical and Molecular Genetics of Psychotic Depression
Domschke, K. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt040 · Cited by 55
Pałucha-Poniewiera, A., Brański, P., Lenda, T., & Pilc, A. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169730 · Cited by 55
The Antidepressant-like Effect of Ethanol Extract of Daylily Flowers (金針花 Jīn Zhēn Huā) in Rats
Lin, S.-H., Chang, H.-C., Chen, P.-J., Hsieh, C., Su, K., & Sheen, L. (2013) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.106548 · Cited by 55
Rubio, F. J., Ampuero, E., Sandoval, R., Toledo, J., Pancetti, F., & Wyneken, U. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00066 · Cited by 54
The Neurobiology of Bipolar Disorder
Young, A. H., & Juruena, M. F. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_179 · Cited by 54
O’Leary, A., Kõiv, K., Hinsley, T. A., Brass, A., & Harro, J. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.09.005 · Cited by 54
Phosphorylation of MeCP2 at Ser421 Contributes to Chronic Antidepressant Action
Hutchinson, A. N., Deng, J. V., Cohen, S., & West, A. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2156-12.2012 · Cited by 53
“These antidepressants are of particular clinical interest because ketamine and scopolamine more rapidly alleviate depression-like symptoms within hours to days of treatment (Zarate et al., 2006; Sanacora et al., 2008; Autry et al., 2011).”
BackgroundZhang, D., Shen, Q., Wu, X., & Xing, D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6678276 · Cited by 53
AMPA receptor positive allosteric modulators: a patent review
Pirotte, B., Francotte, P., Goffin, E., & de Tullio, P. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.770840 · Cited by 52
Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., Bonifacino, T., Mallei, A., Baldelli, P., Racagni, G., et al. (2010) · PLoS ONE · doi:10.1371/annotation/101dd9d3-4e1b-4863-9473-bbfef49c9a1d · Cited by 52
Region-specific glutamate changes in patients with unipolar depression
Grimm, S., Luborzewski, A., Schubert, F., Merkl, A., Kronenberg, G., Colla, M., Heuser, I., & Bajbouj, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.04.018 · Cited by 52
“Evidence from numerous studies suggests that glutamatergic neurotransmission plays a critical role in the pathophysiology of mood disorders (Zarate et al., 2002; Sanacora et al., 2008; Mathewet al., 2008; Yüksel and Ongur, 2010).”
BackgroundThe role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52
Presynaptic Glutamatergic Dysfunction in Bipolar Disorder
Chen, G., Henter, I. D., & Manji, H. K. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.027 · Cited by 52
Self-citationα2-Adrenoceptors are targets for antipsychotic drugs
Brosda, J., Jantschak, F., & Pertz, H. H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3459-8 · Cited by 52
Could glutamate spectroscopy differentiate bipolar depression from unipolar?
Taylor, M. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.019 · Cited by 52
Venâncio, A. M., Marchioro, M., Estevam, C. D. S., Seabra, M. S. D. M., de Santana, M. T., Onofre, A. S. C., Guimarães, A. G., de Oliveira, M. G. B., Alves, P. B., Pimentel, H. D. C., et al. (2011) · Revista Brasileira de Farmacognosia · doi:10.1590/s0102-695x2011005000147 · Cited by 52
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015430 · Cited by 50
Li, W., Ju, K., Li, Z., He, K., Chen, J., Wang, Q., Yang, B., An, L., Feng, G., Sun, W., et al. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.05.004 · Cited by 51
Rodent models of treatment-resistant depression
Caldarone, B. J., Zachariou, V., & King, S. L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.063 · Cited by 50
Cunha, M. P., Pazini, F. L., Ludka, F. K., Rosa, J. M., Oliveira‐Giacomelli, Á., Budni, J., Ramos-Hryb, A. B., Lieberknecht, V., Bettio, L. E. B., Martin‐de‐Saavedra, M. D., et al. (2015) · Amino Acids · doi:10.1007/s00726-014-1910-0 · Cited by 50
Irvine, M. W., Costa, B. M., Volianskis, A., Fang, G., Ceolin, L., Collingridge, G. L., Monaghan, D. T., & Jane, D. E. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2011.12.020 · Cited by 50
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Reus, G. Z., de Moura, A. B., Silva, R. H., Resende, W. R., & Quevedo, J. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170630164715 · Cited by 49
Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice
Neis, V. B., Moretti, M., Manosso, L. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.12.009 · Cited by 49
Laugeray, A., Launay, J.-M., Callebert, J., Mutlu, O., Guillemin, G. J., Belzung, C., & Barone, P. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164337 · Cited by 40
Oligodendroglia-lineage cells in brain plasticity, homeostasis and psychiatric disorders
Birey, F., Kokkosis, A. G., & Aguirre, A. A. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.09.016 · Cited by 49
Jia, N., Li, Q., Sun, H., Song, Q., Tang, G., Sun, Q., Wang, W., Chen, R., Li, H., & Zhu, Z. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1565-6 · Cited by 48
Metabotropic glutamate receptors as emerging research targets in bipolar disorder
Blacker, C. J., Lewis, C. P., Frye, M. A., & Veldić, M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.059 · Cited by 48
Nagy, C., Vaillancourt, K., & Turecki, G. (2018) · Genes, Brain and Behavior · doi:10.1111/gbb.12446 · Cited by 44
Ward, S. E., Harries, M. H., Aldegheri, L., Andreotti, D., Ballantine, S. P., Bax, B. D., Harris, A. J., Harker, A. J., Lund, J., Melarange, R. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1005429 · Cited by 48
Mismatch negativity in bipolar disorder: A neurophysiological biomarker of intermediate effect?
Hermens, D. F., Chitty, K. M., & Kaur, M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.026 · Cited by 48
Carter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., et al. (2020) · International Review of Psychiatry · doi:10.1080/09540261.2020.1765748 · Cited by 47
Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine
Hashimoto, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.176 · Cited by 47
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.